Lapatinib and RAD-001 for HER2 Positive Metastatic Breast Cancer
Status:
Unknown status
Trial end date:
2017-04-01
Target enrollment:
Participant gender:
Summary
By doing this study, researchers hope to learn the effectiveness of the combination of
Lapatinib and RAD-001 for treating patients who have progressed on previous therapies.